Tumor suppressor activity of RIG-I

por Li, Xian-Yang, Guo, He-Zhou, Zhu, Jiang
Publicado 2014

Review immune response of targeting CD39 in cancer

por Liu, Yao, Li, Zhongliang, Zhao, Xiaoguang, Xiao, Jing, Bi, Jiacheng, Li, Xian-Yang, Chen, Guokai, Lu, Ligong
Publicado 2023

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma

por Li, Wenting, Duan, Xiaobing, Chen, Xingxing, Zhan, Meixiao, Peng, Haichuan, Meng, Ya, Li, Xiaobin, Li, Xian-Yang, Pang, Guofu, Dou, Xiaohui
Publicado 2023

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

por Lu, Ligong, Zhan, Meixiao, Li, Xian-Yang, Zhang, Hui, Dauphars, Danielle J., Jiang, Jun, Yin, Hua, Li, Shi-You, Luo, Sheng, Li, Yong, He, You-Wen
Publicado 2022

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms

por Li, Xian-Yang, Das, Indrajit, Lepletier, Ailin, Addala, Venkateswar, Bald, Tobias, Stannard, Kimberley, Barkauskas, Deborah, Liu, Jing, Aguilera, Amelia Roman, Takeda, Kazuyoshi, Braun, Matthias, Nakamura, Kyohei, Jacquelin, Sebastien, Lane, Steven W., Teng, Michele W.L., Dougall, William C., Smyth, Mark J.
Publicado 2022

ACKR4 restrains antitumor immunity by regulating CCL21

por Whyte, Carly E., Osman, Maleika, Kara, Ervin E., Abbott, Caitlin, Foeng, Jade, McKenzie, Duncan R., Fenix, Kevin A., Harata-Lee, Yuka, Foyle, Kerrie L., Boyle, Sarah T., Kochetkova, Marina, Aguilera, Amelia Roman, Hou, Jiajie, Li, Xian-Yang, Armstrong, Mark A., Pederson, Stephen M., Comerford, Iain, Smyth, Mark J., McColl, Shaun R.
Publicado 2020